title: Current and future trends in treatment of severe retinopathy of prematurity.
abstract: Treatment for retinopathy of prematurity (ROP) is indicated when type 1 disease is present. The Early Treatment for Retinopathy of Prematurity (ETROP) clinical trial established that laser treatment of severe ROP has a high rate of visual and anatomic success. Recently, anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab have been used in lieu of or in addition to laser treatment. Results are promising, but long-term outcomes and systemic side effects are unknown. Future studies are needed to determine whether anti-VEGF treatment is superior to laser and, if so, which drug and dose are safe and effective.
authors.affiliation: Department of Ophthalmology and Pediatrics, Duke Eye Center, Durham, NC 27710, USA. david.wallace@duke.edu
authors.forename: David K
authors.initials: DK
authors.lastname: Wallace
authors.forename: Katherine Y
authors.initials: KY
authors.lastname: Wu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D006801:Humans; D007231:Infant, Newborn; D017075:Laser Coagulation; D016032:Randomized Controlled Trials as Topic; D012178:Retinopathy of Prematurity / Q000145:classification / Q000188:drug therapy* / Q000601:surgery; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab